ATP13A2 activators are a group of chemicals that enhance the function of the ATP13A2 protein, also known as PARK9, which is a type of P-type ATPase believed to be involved in the active transport of polyamines, cations, and other substrates across membranes. ATP13A2 has been associated with the maintenance of lysosomal and mitochondrial integrity, playing a role in the cellular degradation pathways and ion homeostasis.
Direct activators of ATP13A2 typically increase the protein's ATPase activity, which is essential for its function as a transporter. They may bind to the ATP-binding sites of the protein, stabilizing conformations that are more efficient in hydrolyzing ATP, the energy source that drives the transport mechanism. Alternatively, these activators might interact with other regulatory domains of ATP13A2 to enhance its substrate affinity or to facilitate the proper localization of the protein within the cell, thereby increasing its functional activity. Indirect activators of ATP13A2 may work by influencing the expression of the ATP13A2 gene, leading to increased protein synthesis. They might also modulate the protein's activity by affecting the lipid composition of the lysosomal membrane, which can alter the optimal environment for ATP13A2 function. Additionally, indirect activators could influence post-translational modifications of the protein, such as phosphorylation or ubiquitination, which may be critical for its activation and stability.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin increases cAMP levels, which can activate cAMP-dependent protein kinase (PKA) and influence lysosomal function and potentially ATP13A2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, leading to the activation of autophagy, a process in which ATP13A2 is involved. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine inhibits lysosomal acidification, which can modulate lysosomal functions and potentially influence ATP13A2. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 inhibits V-ATPase, affecting lysosomal acidification and potentially modulating ATP13A2. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil blocks calcium channels, which can affect calcium homeostasis, a process involved in ATP13A2 function. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A inhibits calcineurin, which can modulate calcium signaling and potentially influence ATP13A2. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine is a calcium channel blocker that can affect calcium homeostasis, a process involved in ATP13A2 function. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene inhibits ryanodine receptors, affecting calcium signaling and potentially modulating ATP13A2. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $219.00 $765.00 | 19 | |
Ryanodine modulates ryanodine receptors, affecting calcium signaling and potentially influencing ATP13A2. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the SERCA pump, disrupting calcium homeostasis, a process involved in ATP13A2 function. |